Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehira Saji

Showing results (1-10 of 247) with videos related to

Pageof 25
Sort By:
Breast Cancer (Tokyo, Japan)|May 30, 2018
The long and winding road for overcoming resistance to hormone therapy in breast cancerShigehira Saji
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 10, 2013
Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxaneShigehira Saji
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Molecular targeting agent to steroid hormone synthesis; aromatase inhibitor]Shigehira Saji
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 18, 2024
[Improved Outcomes in Advanced Metastatic Breast Cancer]Shigehira Saji
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 15, 2007
[The differences of standard therapy for breast cancer between Europe/America and Japan--chemotherapy, operation,and radiotherapy]Dai Kitagawa, Shigehira Saji
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 19, 2015
[Leanness, obesity, and breast cancer risk-different impact of body weight on breast cancer risk according to women's life stages]Reiko Suzuki, Shigehira Saji
Breast Cancer (Tokyo, Japan)|July 26, 2008
Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic natureShigehira Saji, Katsumasa Kuroi
Expert Opinion on Emerging Drugs|July 2, 2005
Aromatase inhibitors and other novel agents in breast cancer treatmentShigehira Saji, Masakazu Toi
International Journal of Clinical Oncology|February 25, 2015
Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancerShigehira Saji, Reiko Kimura-Tsuchiya
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Clinical pharmacology of targeted drug for breast cancer]Hiroshi Ishiguro, Shigehira Saji, Masakazu Toi
Pageof 25

Showing results (1-10 of 247) with videos related to

Sort By:
Pageof 25
Breast Cancer (Tokyo, Japan)|May 30, 2018
The long and winding road for overcoming resistance to hormone therapy in breast cancerShigehira Saji
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 10, 2013
Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxaneShigehira Saji
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Molecular targeting agent to steroid hormone synthesis; aromatase inhibitor]Shigehira Saji
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 18, 2024
[Improved Outcomes in Advanced Metastatic Breast Cancer]Shigehira Saji
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 15, 2007
[The differences of standard therapy for breast cancer between Europe/America and Japan--chemotherapy, operation,and radiotherapy]Dai Kitagawa, Shigehira Saji
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 19, 2015
[Leanness, obesity, and breast cancer risk-different impact of body weight on breast cancer risk according to women's life stages]Reiko Suzuki, Shigehira Saji
Breast Cancer (Tokyo, Japan)|July 26, 2008
Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic natureShigehira Saji, Katsumasa Kuroi
Expert Opinion on Emerging Drugs|July 2, 2005
Aromatase inhibitors and other novel agents in breast cancer treatmentShigehira Saji, Masakazu Toi
International Journal of Clinical Oncology|February 25, 2015
Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancerShigehira Saji, Reiko Kimura-Tsuchiya
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Clinical pharmacology of targeted drug for breast cancer]Hiroshi Ishiguro, Shigehira Saji, Masakazu Toi
Pageof 25